In 2023, Vetoquinol Celebrates Its 90th Anniversary
12 Junho 2023 - 12:45PM
Business Wire
Growth driven by innovation
90 years of innovation
Regulatory News:
Vetoquinol (Paris:VETO):
Ever since the company was founded in 1933, innovation has been
a major component of Vetoquinol's development strategy. Far from
limiting itself to finding new active ingredients or new medicines,
Research and Development (R&D) has also focused on extending
the uses, target species and distribution areas of existing
products.
Over the years, innovation has enabled the company to focus on
strong therapeutic areas and targeted species to make optimal use
of its resources. Vetoquinol invests over €30 million every year in
R&D.
This investment enables us to conduct ambitious research
programs aimed at bringing therapeutic innovation. R&D focuses
on the development of breakthrough innovations, as well as
incremental innovations and the evolution of existing products.
These product innovations, coupled with digital technology and
the diagnostics offered by Vetoquinol, enable us to respond
differently and better to the expectations of breeders, pet owners
and veterinarians. In this way, Vetoquinol strives to offer its
customers full fledge solutions that meet their needs by
integrating the essential elements required for a result that
satisfies their expectations.
Innovation on all fronts
Vetoquinol's R&D department develops numerous initiatives to
broaden, support or complement the company's activities.
- Partnerships with private and public bodies to initiate
ground-breaking innovation projects.
- Regular publications in recognized scientific journals, patent
filings, applications for Marketing Authorizations (MA) and the
development of a network of scientific experts.
- Anticipating regulatory changes in the field of veterinary
drugs and customer behavior.
The aim of these initiatives is to provide the best possible
service to veterinary customers, breeders and pet owners.
A strong presence in France
Vetoquinol's R&D is mainly located in France, with the
center of expertise and scientific excellence based at the
company's headquarters in the east of France in Lure
(Franche-Comté). Today, Vetoquinol’s R&D department employs
nearly 180 people, including some 60 scientific managers and 100
researchers, to respond to current animal health issues.
The primary role of R&D is to develop drugs for registration
in the countries where Vetoquinol operates or distributes its
products. That's why Vetoquinol has product development units all
over the world (France, United States, Poland, Brazil), which
contribute to the company’s reputation.
ABOUT VETOQUINOL
Vetoquinol is a leading global animal health company that
supplies drugs and non-medicinal products for the farm animals
(cattle and pigs) and pet (dogs and cats) markets. As an
independent pure player, Vetoquinol designs, develops and sells
veterinary drugs and non-medicinal products in Europe, the Americas
and the Asia Pacific region. Since its foundation in 1933,
Vetoquinol has pursued a strategy combining innovation with
geographical diversification. The Group’s hybrid growth is driven
by the reinforcement of its product portfolio coupled with
acquisitions in high potential growth markets. Vetoquinol employed
more than 2,500 people as of December 31st, 2022.
Vetoquinol has been listed on Euronext Paris since 2006 (symbol:
VETO).
The Vetoquinol share is eligible for the French PEA and PEA-PME
personal equity plans.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230612202136/en/
VETOQUINOL Group Communications Officer Resika
Narain-Menigot resika.narain-menigot@vetoquinol.com KEIMA
COMMUNICATION Press Relations Charles-Edouard Aubry
Tel.: +33 (0)6 09 09 48 32 charles-edouard.aubry@keima.fr
Investors Relations Emmanuel Dovergne Tel.: +33 (0)6
76 94 40 87 emmanuel.dovergne@keima.fr
Vetoquinol (EU:VETO)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Vetoquinol (EU:VETO)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024